Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data

Clinical studies after marketing have shown that the use of glucagon-like peptide-1 receptor agonist(GLP-1RA) may lead to acute kidney injury(AKI). However, few epidemiological studies have investigated the risk, clinical features, and outcomes of AKI caused by different GLP-1RA. In this study, Adve...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Shichao, Sun, Chuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792852/
https://www.ncbi.nlm.nih.gov/pubmed/36583004
http://dx.doi.org/10.3389/fendo.2022.1032199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792852/
https://www.ncbi.nlm.nih.gov/pubmed/36583004
http://dx.doi.org/10.3389/fendo.2022.1032199

Ejemplares similares